Anti-inflammatory, membrane-stabilizing interactions of salmeterol with human neutrophils in vitro

British Journal of Pharmacology

Volumn 117, Issue 7, 1996, Pages 1387-1394

  Anderson, R ^a,d   Feldman, C ^b   Theron, A J ^a   Ramafi, G ^a   Cole, P J ^c   Wilson, R ^c  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d Department of Immunology ^*  (South Africa)

Author keywords

Lysophospholipids; Membrane stabilization; Neutrophils; Oxidants; Platelet activating factor; Salmeterol

Indexed keywords

1 O ALKYLGLYCERO 3 PHOSPHORYLCHOLINE; CALCIMYCIN; CALCIUM; FENOTEROL; FORMOTEROL; LYSOPHOSPHATIDYLCHOLINE; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHOLIPASE A2; PROPRANOLOL; SALBUTAMOL; SALMETEROL; SUPEROXIDE; THROMBOCYTE ACTIVATING FACTOR; ZYMOSAN;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ASTHMA; CALCIUM CELL LEVEL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVITY; HEMOLYSIS; HUMAN; HUMAN CELL; MEMBRANE STABILIZATION; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT;

EID: 0030004877     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15297.x     Document Type: Article

References (33)

1. ADVENIER, C., QIAN, Y., LAW KOUNE, J.-D., MOLIMARD, M., CANDENAS, M.-L & NALINE, E. (1992). Formoterol and salmeterol inhibit bradykinin and histamine induced airway microvascular leakage in guinea-pig. Br. J. Pharmacol., 105, 792-798.
2. 2, but not protein kinase C, in the pro-oxidative interactions of clofazimine with human phagocytes. Biochem. Pharmacol., 37, 4635-4641.
3. BAKER, A.J. & FULLER, R.W. (1990). Anti-inflammatory effect of salmeterol on human alveolar macrophages. Am. Rev. Resp. Dis., 141, A394.
4. BARNES, P.J. (1989). New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma. J. Allergy Clin. Immunol., 83, 1013-1026.
5. 2 for activation of the assembled NADPH-oxidase in human neutrophils. Biochem. J., 297, 217-223.
6. EDA, R., SUGIYAMA, H., HOPP, R.J., OKADA, C., BEWTRA, A.K. & TOWNLEY, R.G. (1993). Inhibitory effects of formoterol on platelet-activating factor induced eosinophil chemotaxis and degranulation. Int. Arch. Allergy Appl. Immunol., 102, 391-398.
7. ENGELBERGER, W., BITTER-SUERMANN, D. & HADDING, U. (1987). Influence of lysophospholipids and PAF on the oxidative burst. Int. J. Immunopharmacol., 9, 275-282.
8. ERJEFALT, I & PERRSON, C.G.A. (1991). Long duration and high potency of antiexudative effects of formoterol in guinea-pig tracheobronchial airways. Am. Rev. Resp. Dis. 144, 788-791.
9. FELDMAN, C., ANDERSON, R., THERON, A., COLE, P.J. & WILSON, R. (1995). The effects of platelet activating factor (PAF) and lysophosphatidylcholine (LPC) on human ciliated epithelium in vitro. Am. J. Resp. Crit. Care Med., 151, A65.
10. FUGNER, A. (1989). Formation of oedema and accumulation of eosinophils in the guinea-pig lung. Inhibition by beta-stimulants. Int. Arch. Allergy Appl. Immunol., 88, 225-227.
11. GANBO, T., HISAMATSU, K., NAKAZAWA, T., KAMJO, A. & MURAKAMI, Y. (1991). Platelet activating factor (PAF) effects on ciliary activity of human paranasal sinus mucosa in vitro. Rhinology, 29, 231-237.
12. 2 which is related to phenol rings within the molecular structure. Am. J. Resp. Crit. Care Med., 151, A270.
13. 2 in vitro. Am. J. Resp. Crit. Care Med., 149, A805.
14. GINSBURG, I., WARD, P.A. & VARANI, J. (1989). Lysophosphatides enhance superoxide responses of stimulated human neutrophils. Inflammation, 13, 163-174.
15. GREENING, A.P., IND, P.W., NORTHFIELD, M. & SHAW, G. (1994). Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet, 344, 219-224.
16. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem., 260, 3440-3450.
17. HOLMSEN, H.E., STORM, E. & DAY, H.J. (1972). Determination of ATP and ADP in blood platelets: a modification of the firefly luciferase assay for plasma. Anal. Biochem., 46, 481-502.
18. JOHNSON, M. (1995). Approaches to the design of long-acting agonists at β-adrenoceptors. In β-Adrenoceptor Agonists and the Airways, ed. Johnson, M. & Small, R. pp. 13-27. London: Royal Society of Medicine Press Ltd.
19. KANTHAKUMAR, K., CUNDELL, D.R., JOHNSON, M., WILLS, P.J., TAYLOR, G.W., COLE, P.J. & WILSON, R. (1994). Effect of salmeterol on human nasal epithelial cell ciliary beating: inhibition of the ciliotoxin, pyocyanin. Br. J. Pharmacol., 112, 493-498.
20. KUSNER, D.J., AUCOTT, J.N., FRANCESCHI, D., SARASUA, M.M., SPAGNUOLO, P.J. & KING, C.H. (1991). Protease priming of neutrophil superoxide production: effects on membrane lipid order and lateral mobility. J. Biol. Chem., 266, 16465-16471.
21. MARQUARDT, D. & WALKER, L.L. (1991). Lysophosphatidylcholine induces mast cell secretion and protein kinase C activation. J. Allergy Clin. Immunol., 88, 721-730.
22. 2 activity and plasma lysophosphatidylcholine levels in asthma and rhinitis and their relationship to airway sensitivity to histamine. Am. Rev. Resp. Dis., 142, 157-161.
23. MINKENBERG, I. & FERBER, E. (1984). Lucigenin-dependent chemiluminescence as a new assay for NADPH-oxidase activity in particulate fractions of human polymorphonuclear leukocytes. J. Immunol. Methods, 71, 61-67.
24. NACCACHE, P.H., MCCOLL, S.R., CAON, A.C. & BORGEAT, P. (1989). Arachidonic acid-induced mobilisation of calcium in human neutrophils: evidence for a multicomponent mechanism of action. Br. J. Pharmacol., 97, 461-468.
25. 4 in man. Eur. Respir. J., 4, 551-560.
26. OISHI, K., RAYNOR, R.L., CHARP, P.A. & KUO, J.F. (1988). Regulation of protein kinase C by lysophospholipids. J. Biol. Chem., 263, 6865-6871.
27. 2-agonist. J. Allergy Clin. Immunol., 89, 844-849.
28. RAMAGE, L., BLAIR, A., CREE, I.A. & DHILLON, D.P. (1993). Effect of salmeterol on polymorphonuclear leukocyte (PMNL) chemiluminescence in vitro. J. Biolumin. Chemilumin., 8, 247-252.
29. TWENTYMAN, O.P., FINNERTY, J.P., HARRIS, A., PALMER, J. & HOLGATE, S.T. (1990). Protection against allergen-induced asthma by salmeterol. Lancet, 336, 1338-1342.
30. VARDEY, C.J., NIALS, A.T. & COLEMAN, R.A. (1994). Inhibitory effects of salmeterol in human neutrophils are short-lasting. Am. J. Resp. Crit. Care Med., 149, A361.
31. WHELAN, C.J., JOHNSON, M. & VARDEY, C.J. (1993). Comparison of the anti-inflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung. Br. J. Pharmacol., 110, 613-618.
32. WILES, M.E., DYKENS, J.A. & WRIGHT, C.D. (1994). Regulation of polymorphonuclear leukocyte membrane fluidity: effect of cytoskeletal modification. J. Leuk. Biol., 56, 192-199.
33. ZIMMERMAN, G.A., PRESCOTT, S.M. & MCINTYRE, T.M. (1992). Platelet-activating factor: a fluid phase and cell-associated mediator of inflammation. In Inflammation: Basic Principles and Clinical Correlates, ed. Gallin, J.I., Goldstein, I.M. & Snyderman, R. pp. 149-176. New York: Raven Press Ltd.